Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity

Thyroid cancer is the most common endocrine neoplasm, and despite its overall high survival rate, patients with metastatic disease or tumors that resist radioactive iodine experience a significantly worse prognosis. Helping these patients requires a better understanding of how therapeutics alter cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolf, Eric L., Beadnell, Thomas C., Rose, Madison M., D’Alessandro, Angelo, Nemkov, Travis, Hansen, Kirk C., Schweppe, Rebecca E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216321/
https://www.ncbi.nlm.nih.gov/pubmed/37408209
http://dx.doi.org/10.3390/cells12101374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216321/
https://www.ncbi.nlm.nih.gov/pubmed/37408209
http://dx.doi.org/10.3390/cells12101374

Ejemplares similares